| 1361 |
National Cancer Institute |
Html |
en |
Esophageal Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of esophageal cancer. |
| esophageal mucosa | 0.388276 |
| Surg Gynecol Obstet | 0.322065 |
| upper thoracic esophagus | 0.424827 |
| Engl J Med | 0.487637 |
| oesophageal cancer | 0.359132 |
| esophagus extends | 0.400639 |
| Gastrointest Endosc | 0.369631 |
| preoperative chemotherapy | 0.369817 |
| Ann Surg Oncol | 0.343391 |
| Radiation Therapy Oncology | 0.363113 |
| lower esophagus | 0.428306 |
| randomized trial | 0.366127 |
| patients | 0.358564 |
| thermal ablation therapy | 0.326198 |
| Coll Surg | 0.323431 |
| esophageal obstruction | 0.464185 |
| cervical esophagus | 0.414894 |
| esophageal adenocarcinoma | 0.376246 |
| endoscopic laser therapy | 0.333059 |
| radiation therapy | 0.485551 |
| partial esophageal obstruction | 0.426095 |
| esophageal carcinoma | 0.425086 |
| Malignant esophageal obstruction | 0.414655 |
| et al. | 0.60539 |
| esophageal cancers results | 0.439813 |
|
| surgery versus surgery | 0.374104 |
| esophageal cancer | 0.911438 |
| multicenter randomized trial | 0.34111 |
| Therapy Oncology Group | 0.366143 |
| PUBMED Abstract | 0.490901 |
| Surgical treatment | 0.372648 |
| advanced esophageal cancer | 0.428676 |
| locoregional esophageal carcinoma | 0.419242 |
| Thorac Cardiovasc Surg | 0.334758 |
| Semin Surg Oncol | 0.357463 |
| definitive radiation therapy | 0.326973 |
| complete esophageal obstruction | 0.428536 |
| Abstract | 0.52332 |
| Clin Oncol | 0.7331 |
| Council Oesophageal Cancer | 0.337988 |
| inoperable malignant dysphagia | 0.325697 |
| junctional cancer | 0.327281 |
| Minimally invasive surgery | 0.326119 |
| van Sandick JW | 0.37682 |
| van Lanschot JJ | 0.562871 |
| chemoradiation versus surgery | 0.346134 |
| esophagus | 0.550763 |
| phase III trial | 0.333959 |
| squamous cell carcinoma | 0.57882 |
|
CLICK HERE |
| 1751 |
National Cancer Institute |
Html |
en |
Hospice Care |
A fact sheet about hospice care, including insurance coverage. |
| palliative care share | 0.4463 |
| home health | 0.436046 |
| hospice programs | 0.663338 |
| hospice team | 0.740949 |
| specific care decisions | 0.42786 |
| hospice doctor | 0.624846 |
| spiritual support | 0.408056 |
| public health departments | 0.391127 |
| American Cancer Society | 0.455655 |
| hospice services | 0.722561 |
| home health aides | 0.405139 |
| state Medicaid office | 0.402126 |
| nursing care | 0.391635 |
| hospice medical director | 0.768439 |
| Hospice Association | 0.649826 |
| cancer care | 0.409838 |
| hospital business office | 0.388593 |
| life expectancy | 0.408587 |
| hospice team member | 0.685192 |
| special in-patient facilities | 0.500987 |
| Medicare website | 0.415518 |
| specific state locations | 0.392604 |
| government health insurance | 0.402081 |
| sheet Palliative Care | 0.444628 |
| state social services | 0.40519 |
|
| nursing homes | 0.407681 |
| end-of-life care | 0.424373 |
| health aide services | 0.410795 |
| hospice organizations | 0.592662 |
| Palliative Care Organization | 0.507564 |
| private insurance plans | 0.399019 |
| Hospice Net | 0.623257 |
| palliative care | 0.604188 |
| Medicare coverage | 0.386456 |
| national hospice | 0.673933 |
| regional home health | 0.398589 |
| national hospice programs | 0.634262 |
| hospice care | 0.982488 |
| local state welfare | 0.391739 |
| health insurance plans | 0.419219 |
| Medicare benefits | 0.388255 |
| hospice expenses | 0.700651 |
| insurance plans | 0.503978 |
| federal-state partnership program | 0.389089 |
| Medicare Hospice Benefits | 0.695621 |
| Medicare-certified hospice programs | 0.660409 |
| Respite Care page | 0.429976 |
| social work services | 0.407475 |
| free fact sheets | 0.38648 |
|
CLICK HERE |
| 1910 |
National Cancer Institute |
Html |
es |
Tratamiento de los tumores carcinoides gastrointestinales (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento de los tumores carcinoides gastrointestinales. |
| tejido tumoral carcinoide | 0.303641 |
| electrodos minúsculos | 0.300961 |
| tumor carcinoide | 0.379006 |
| siguientes procedimientos | 0.32226 |
| pequeña cámara | 0.300969 |
| pequeña cantidad | 0.300995 |
| claro cuál | 0.301673 |
| rayos x | 0.301155 |
| tumores carcinoides gi | 0.541315 |
| cromogranina a | 0.301286 |
| ondas sonoras | 0.301178 |
| sÃndrome carcinoide | 0.405552 |
| pequeño efecto | 0.300747 |
| tumores neuroendocrinos | 0.31718 |
| National Cancer Institute | 0.300501 |
| tumores carcinoide gi | 0.305034 |
|
| siguientes riesgos | 0.300555 |
| endocrina múltiple tipo | 0.30275 |
| Instituto Nacional | 0.300956 |
| PDQ Tratamiento | 0.301284 |
| neurofibromatosis tipo | 0.301611 |
| tubo gi | 0.311684 |
| Physician Data Query | 0.302032 |
| pimientos chili | 0.300797 |
| carcinoides gi recidivantes | 0.302839 |
| Antecedentes familiares | 0.301159 |
| cuerpo cantidades | 0.303122 |
| hÃgado ayuda | 0.301344 |
| tumores carcinoides | 0.989957 |
| tumor carcinoide gi | 0.311705 |
| siguientes sumarios | 0.303432 |
| células neuroendocrinas | 0.30282 |
|
CLICK HERE |
| 1967 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de pene (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de pene. |
| siguientes procedimientos | 0.765966 |
| siguientes aspectos | 0.663436 |
| radiosensibilizadores ayuda | 0.608332 |
| estadio ii | 0.653561 |
| ganglio linfático centinela | 0.99757 |
| rayos x | 0.61452 |
| menor cantidad | 0.630187 |
| enlace drugs approved | 0.616023 |
| ondas sonoras | 0.614903 |
| National Cancer Institute | 0.60451 |
| siguientes riesgos | 0.604706 |
| papiloma virus | 0.656514 |
| únicos tratamientos | 0.60726 |
|
| Instituto Nacional | 0.609778 |
| Penile Cancer | 0.60882 |
| estadio iiia | 0.623114 |
| PDQ Tratamiento | 0.608893 |
| cuerpo esponjoso | 0.725663 |
| presente sección | 0.608144 |
| Physician Data Query | 0.620917 |
| siguientes sitios | 0.675658 |
| siguientes operaciones | 0.617884 |
| órgano masculino | 0.616691 |
| siguientes pruebas | 0.65372 |
| siguientes estadios | 0.621615 |
|
CLICK HERE |
| 2080 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de testículo (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de testículo. |
| estadios tardÃos | 0.651471 |
| Visuals Online | 0.570773 |
| PDQ Exámenes | 0.759721 |
| Physician Data Query | 0.918778 |
| testÃculos.ampliar anatomÃa | 0.643812 |
| mejores tratamientos | 0.631067 |
| prevención revisa | 0.590052 |
|
| sistema urinario masculino | 0.76274 |
| glándulas sexuales masculinas | 0.790025 |
| información ayuda | 0.600632 |
| National Cancer Institute | 0.62598 |
| siguientes riesgos | 0.575127 |
| Instituto Nacional | 0.738066 |
|
CLICK HERE |
| 3427 |
National Cancer Institute |
Html |
es |
Terapia láser para el tratamiento del cáncer |
Hoja informativa que describe el uso de una luz de alta intensidad en el tratamiento del cáncer, sus ventajas y desventajas, y los tipos de procedimientos que la utilizan. |
| usa calor | 0.497681 |
| luz solar | 0.504529 |
| terapia láser usa | 0.846675 |
| usa rayos | 0.615014 |
| sustancia fotosensibilizadora | 0.467924 |
|
| alta intensidad | 0.607112 |
| terapia láser causa | 0.851667 |
| áreas minúsculas | 0.473045 |
| determinados sÃntomas | 0.470796 |
|
CLICK HERE |
| 3880 |
National Cancer Institute |
Html |
es |
Extractos de muérdago (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos sobre el uso de los extractos de muérdago como tratamiento para personas con cáncer. |
| from mistletoe extract | 0.31162 |
| Cancer Res Clin | 0.306787 |
| mistletoe extracts | 0.396569 |
| album extract isorel | 0.309539 |
| Mistletoe extracts standardised | 0.30709 |
| viscum album | 0.980886 |
| galactoside-specific lectin from | 0.335383 |
| thionins from viscum | 0.3152 |
| muérdago i | 0.308032 |
| treated with viscum | 0.312029 |
| Cancer Res | 0.31513 |
| isolated from viscum | 0.307496 |
| extracto viscum album | 0.308065 |
| Viscum album agglutinin-induced | 0.308373 |
| with viscum album | 0.33586 |
| from viscum album | 0.472392 |
| beta-galactoside-specific lectin from | 0.310754 |
| Hajto T | 0.314595 |
| extract from viscum | 0.316835 |
| Viscum album enhancing | 0.30854 |
| patients with | 0.307472 |
| thionins from european | 0.306901 |
| Immunomodulatory Agents from | 0.306741 |
| viscum album extract | 0.338924 |
| viscum album l | 0.601922 |
|
| Mistletoe lectins as | 0.306952 |
| preparation from viscum | 0.308802 |
| Complement Ther Med | 0.308742 |
| tumor cell | 0.31334 |
| Mistletoe extracts standardized | 0.30726 |
| Beuth J | 0.317637 |
| mistletoe treatment | 0.310143 |
| lectin from | 0.350339 |
| derived from viscum | 0.315008 |
| In vitro effects | 0.312037 |
| Schaller G | 0.307482 |
| blood mononuclear cells | 0.315901 |
| subspecies viscum album | 0.308835 |
| lectin from viscum | 0.322905 |
| Gabius HJ | 0.329931 |
| Viscum album induces | 0.316269 |
| ml1 from viscum | 0.307567 |
| breast cancer | 0.326075 |
| Viscum album species | 0.308916 |
| plant lectin | 0.306716 |
| mistletoe lectins | 0.449053 |
| in vitro | 0.456679 |
| Hostanska K | 0.309958 |
| fermented extract from | 0.30821 |
|
CLICK HERE |
| 15645 |
National Cancer Institute |
Html |
en |
Legal Requirements |
Research grants are subject to many requirements from a variety of legal authorities, with the broadest being the U.S. Constitution. |
| Grants Management Officer | 0.556816 |
| United States Code | 0.420323 |
| research grants | 0.615532 |
| basic substantive legislation | 0.444546 |
| program requirements | 0.352641 |
| to-date policy guidance | 0.408228 |
| general regulations | 0.340444 |
| federal agency | 0.352362 |
| federal regulations | 0.501493 |
| Administrative Procedures Act | 0.389735 |
| NIH standard terms | 0.534403 |
| NIH Grants Policy | 0.868204 |
| research grant policies | 0.404926 |
| reasonable conditions | 0.340026 |
| research community | 0.390073 |
| appropriation legislation | 0.37075 |
| individual grants | 0.462407 |
| Appropriation bills | 0.343865 |
| NIH contracting offices | 0.525598 |
| legal authorities | 0.328189 |
| issues government-wide circulars | 0.425727 |
| administrative requirements | 0.328069 |
| NCI grants | 0.592028 |
| human subjects protection | 0.399778 |
| grants administration policies | 0.567751 |
|
| Congress | 0.346023 |
| authorize federal agencies | 0.500849 |
| United States | 0.452601 |
| CFR Parts | 0.368971 |
| grants administration decisions | 0.591481 |
| federal Executive agencies | 0.452185 |
| CFR | 0.384291 |
| appropriation laws | 0.351099 |
| Spending Power Clause | 0.442228 |
| United States Constitution | 0.43014 |
| grants administration | 0.689773 |
| grants area | 0.524071 |
| appropriate NIH oversight | 0.528865 |
| grants | 0.962134 |
| program expenditures | 0.33855 |
| requirements | 0.388492 |
| NIH Guide | 0.647123 |
| federal register | 0.490568 |
| federal assistance funds | 0.682098 |
| specific laws | 0.335616 |
| specific program | 0.335203 |
| federal program | 0.371737 |
| Public Health Service | 0.421913 |
| general authority | 0.329535 |
|
CLICK HERE |
| 16653 |
National Cancer Institute |
Html |
en |
IOTF Mentors: Track 3 and Track 4 |
While at FDA, fellows are assigned a mentor who is a senior member of FDA scientific review staff. Learn more about mentors for Tracks 3 and 4. |
| regulatory review | 0.859055 |
| Radiological Health | 0.80074 |
| review process | 0.801152 |
| project | 0.796601 |
| radiation therapy devices | 0.823079 |
| office | 0.805677 |
| Biologics Evaluation | 0.882543 |
| research | 0.878646 |
| therapy medical products | 0.786754 |
| medical products | 0.814349 |
| division | 0.805276 |
| cell-based medical products | 0.805668 |
| Biotechnology Products | 0.814932 |
| research program | 0.805393 |
| cell culture cells | 0.78633 |
| gene therapy products | 0.878795 |
| stem cells | 0.79941 |
| development | 0.787013 |
| cancer risk assessment | 0.792173 |
| gene therapy | 0.961714 |
| nucleic acid | 0.824416 |
| investigational new drug | 0.905511 |
| drug applications | 0.79082 |
| new drug products | 0.789184 |
|
| neoplastic cell substrates | 0.79142 |
| radiation therapy | 0.854476 |
| cancer chemotherapy | 0.787392 |
| radiation therapy treatments | 0.789697 |
| FDA | 0.8111 |
| Drug Evaluation | 0.832004 |
| Drug Administration | 0.845645 |
| cell | 0.852835 |
| therapeutic proteins | 0.875837 |
| cell therapy | 0.796306 |
| regulatory review scientist | 0.807408 |
| iotf fellow | 0.867768 |
| Principal Investigator | 0.803321 |
| Center | 0.786741 |
| early cancer detection | 0.787952 |
| Cancer Health Claims | 0.787284 |
| gene therapies | 0.879766 |
| cells | 0.826854 |
| immune cell activation | 0.789452 |
| fellow | 0.909256 |
| gene therapy applications | 0.81743 |
| cancer risk | 0.812916 |
| new medical products | 0.802617 |
| cancer | 0.939352 |
|
CLICK HERE |
| 16864 |
National Cancer Institute |
Html |
es |
Selected Vegetables y Sun's Soup (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos sobre el uso de Selected Vegetables y Sun's Soup como tratamiento para personas con cáncer. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta. |
| Frozen SV | 0.301838 |
| Sun’s Soup | 0.622837 |
| Selected Vegetables | 0.989854 |
| specific dietary supplement | 0.365272 |
| multi-institutional prospective study | 0.301068 |
| Wang LH | 0.31046 |
| Sun Farm | 0.310084 |
| Instituto Nacional | 0.303518 |
| peso corporal promedio | 0.301106 |
| IV non-small | 0.334303 |
| Estados Unidos | 0.309279 |
| tratamiento simultáneoc puntaje | 0.301389 |
| Sun’s Soup“ | 0.302908 |
| allium cepa l | 0.300921 |
| patients taking | 0.307016 |
| non-small cell lung | 0.365258 |
| Lentinus edodes | 0.303332 |
| Sun Farm Corporation | 0.305751 |
| frijol mungo | 0.301357 |
| alimentario selected vegetables | 0.303781 |
| patients with | 0.301382 |
| investigación clÃnica | 0.301025 |
| glycine max l | 0.300858 |
| Yeh HC | 0.310747 |
| herbal treatment | 0.309558 |
|
| crataegus oxyacantha l | 0.300911 |
| Trademark Office | 0.305198 |
| puntaje promedio | 0.304049 |
| allium bakeri regel | 0.300852 |
| estadio iv | 0.311573 |
| Sun's Soup | 0.425399 |
| Pilot study | 0.310803 |
| glycyrrhiza glabra l | 0.300901 |
| cáncer número | 0.301303 |
| frijoles mungo | 0.303086 |
| Nutr Cancer | 0.335867 |
| US Patent | 0.318672 |
| Ryznar V | 0.306737 |
| Farm Vegetable Soup | 0.306615 |
| Ostadal O | 0.306698 |
| accessed april | 0.311866 |
| porcentaje promedio | 0.301352 |
| allium fistulosum l | 0.300943 |
| Glycine max | 0.301356 |
| Freeze-dried SV | 0.300819 |
| sesamum indicum l | 0.300901 |
| pacientes sà | 0.303642 |
| phaseolus radiatus l | 0.305677 |
| República Checa | 0.301327 |
|
CLICK HERE |